Teladoc Health Files 8-K with Financial Updates
Ticker: TDOC · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1477449
| Field | Detail |
|---|---|
| Company | Teladoc Health, Inc. (TDOC) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
Related Tickers: TDOC
TL;DR
TDOC filed its 8-K on 7/31/24 with financial results - check it for the latest performance.
AI Summary
On July 31, 2024, Teladoc Health, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance for the period ending July 31, 2024. This report is crucial for investors to assess the company's current financial health and strategic direction.
Why It Matters
This 8-K filing provides investors with essential, up-to-date financial information and operational details for Teladoc Health, Inc., enabling informed investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings are routine disclosures, but the specific financial details within can reveal significant positive or negative performance trends.
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- July 31, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 2 Manhattanville Road Suite 203 Purchase, NY 10577 (address) — Principal executive offices
- 203-635-2002 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it includes 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', providing an update on the company's financial performance.
When was this 8-K report filed with the SEC?
The report was filed on July 31, 2024.
What is the primary purpose of this 8-K filing for Teladoc Health, Inc.?
The primary purpose is to report on the company's results of operations and financial condition, as well as to file necessary financial statements and exhibits.
What is Teladoc Health, Inc.'s state of incorporation?
Teladoc Health, Inc. is incorporated in Delaware.
Where are Teladoc Health, Inc.'s principal executive offices located?
The principal executive offices are located at 2 Manhattanville Road, Suite 203, Purchase, NY 10577.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-07-31 16:05:23
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha
Filing Documents
- tdoc-20240731.htm (8-K) — 27KB
- tdoc-20240630xexx991.htm (EX-99.1) — 393KB
- image_0a.jpg (GRAPHIC) — 6KB
- 0001477449-24-000172.txt ( ) — 581KB
- tdoc-20240731.xsd (EX-101.SCH) — 2KB
- tdoc-20240731_lab.xml (EX-101.LAB) — 22KB
- tdoc-20240731_pre.xml (EX-101.PRE) — 13KB
- tdoc-20240731_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On July 31, 2024, Teladoc Health, Inc. (the "Company") issued a press release relating to its financial results for the second quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Teladoc Health, Inc. press release, dated July 31 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Furnished herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2024 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary